LexDanaLexDanabeta
Inventor

Rodger F. Henry

Inventor
Wildwood, IL, US

Overview

35→
Patents
1996–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 35 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds29%
A61KPreparations for medical, dental or toiletry purposes22%
C07CAcyclic or carbocyclic compounds10%
C07BGeneral methods of organic chemistry3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07HSugars2%
PatentTitleYear
10,329,276Salt and crystalline forms thereof of a drug20199,873,681Salt and crystalline forms thereof of a drug20189,539,250'Salt and crystalline forms thereof of a drug'20179,446,059'Carbidopa and L-dopa prodrugs and methods of use'20168,986,740'Anti-infective agents and uses thereof'20158,987,453'Azaadamantane derivatives and methods of use'20158,969,569'Salt and crystalline forms thereof of a drug'20158,796,451'Crystalline pharmaceutical'20148,648,093'Salt and crystalline forms thereof of a drug'20148,399,468'Octahydro-pyrrolo[3,4-B]pyrrole derivatives'20138,362,013'Salt of ABT-263 and solid-state forms thereof'20138,314,119'Azaadamantane derivatives and methods of use'20128,273,892'Salt and crystalline forms thereof of a drug'20128,252,813'Salt and crystalline forms thereof of a drug'20128,178,548'Anti-infective agents and uses thereof'20128,058,433'Crystalline pharmaceutical'20118,034,926'Methods of manufacturing crystalline forms of rapamycin analogs'20118,030,326'Crystalline forms of rapamycin analogs'20117,943,782'Crystalline chemotherapeutic'20117,820,812'Methods of manufacturing crystalline forms of rapamycin analogs'20107,812,032'Crystalline forms of rapamycin analogs'20107,745,622'Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate'20107,745,448'Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate'20107,728,143'Salt and crystalline forms thereof of a drug'20107,589,194'Crystalline k-252b, sodium salt, methanolate pentahydrate'20097,585,972'Crystalline K-252α bis(tetrahydrofuranate)'20097,538,226'(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane'20097,449,584'N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1'20087,446,206'N-((2Z)-2-((4-hydroxyphenyl) amino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2'20087,354,937'(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane'20086,864,369'Crystalline pharmaceutical'20056,627,743'6-O-methylerythromycin A crystal form III'20036,608,198'Crystalline pharmaceutical'20035,945,405'Crystal form O of clarithromycin'19995,504,207'Process and intermediate for the preparation of terazosin hydrochloride dihydrate'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2013Patents assigned to ABBOTT LAB (24)· patent assignee history
1996–1999Based in Waukegan, IL, US· patent location history
2003–2014Based in Park City, IL, US· patent location history
2008–2019Based in Wildwood, IL, US· patent location history
2011–2015Patents assigned to HENRY RODGER F (6)· patent assignee history
2012–2019Patents assigned to ABBVIE INC (11)· patent assignee history
2012–2015Patents assigned to ZHANG GEOFF G Z (8)· patent assignee history
2012–2014Patents assigned to BARNES DAVID M (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ABBOTT LAB241996–2013
ABBVIE INC112012–2019
ZHANG GEOFF G Z82012–2015
HENRY RODGER Fself62011–2015
BARNES DAVID M42012–2014
Locations
LocationPatentsSpan
Wildwood, Illinois, US282008–2019
Park City, Illinois, US52003–2014
Waukegan, Illinois, US21996–1999